Group 1: Insurance Sector - Insurance stocks are experiencing significant declines, with China Life (02628) down 3.75%, New China Life (01336) down 3.28%, and China Pacific Insurance (02601) down 2.74%. The government plans to issue approximately 200 billion yuan in special bonds to inject capital into major insurance companies, marking the first time this method will be used for insurance firms in China [1] Group 2: Logistics and Delivery - ZTO Express (02057) has seen an increase of over 2.3%. The company estimates that its total revenue for 2025 will be between 48.5 billion yuan and 50 billion yuan, representing a growth of approximately 9.5% to 12.9% compared to 44.2807 billion yuan in 2024 [1] Group 3: Biotechnology - Innovent Biologics (09969) has risen over 4%, with a current increase of 3.25%. The company anticipates achieving revenue of 2.37 billion yuan in 2025, a year-on-year growth of approximately 134%, and expects to turn a profit with a net profit of around 630 million yuan [1] Group 4: Coal Sector - Coal stocks are generally declining, with Yancoal Australia (03668) down 6.63%, Shougang Resources (00639) down 7.83%, and China Shenhua (01088) down 2.47%. This decline follows reports that the Indonesian government has proposed a production cut plan, leading to a 40% to 70% reduction in production quotas for major miners [2] Group 5: Medical Devices - GigaGen (02367) has increased over 8%, currently up 4.11%. The company recently announced that its "recombinant type I α1 collagen and sodium hyaluronate composite solution" has been approved as a medical device, marking a significant milestone as the first product of its kind for improving facial smoothness [2] Group 6: Semiconductor Sector - Semiconductor stocks are all declining, with Hua Hong Semiconductor (01347) down 5.91% and SMIC (00981) down 3.49%. This follows a significant drop in AMD's stock price by 17.31% after its fourth-quarter report indicated that while revenue exceeded expectations, the guidance for the first quarter was below market expectations [3] Group 7: Restaurant Sector - Restaurant stocks are performing well, with Yum China (09987) up 8.41% and Haidilao (06862) up 2.69%. The restaurant industry has shown signs of recovery, with retail sales in the sector growing by 3.8%, 3.2%, and 2.2% year-on-year in the last quarter of 2025, significantly outpacing overall retail growth [3] Group 8: Consumer Goods - Miniso (09896) has risen over 5.1% after announcing its partnership with the Central Radio and Television Station for the 2026 Spring Festival Gala. This collaboration is seen as a significant marketing move to elevate the brand's visibility in the mainstream market [4] Group 9: Gold Sector - Gold stocks are declining, with China Gold International (02099) down 6.8% and Zijin Mining (02899) down 6.29%. Recent volatility in the international gold market has been noted, with expectations that geopolitical tensions and liquidity easing by the Federal Reserve may drive gold prices higher [4] Group 10: Cryptocurrency - Cryptocurrency ETFs and related stocks are continuing to decline, with significant drops in prices, including Bitcoin falling below $72,000 for the first time in 15 months. The price has decreased by over 42% from its peak last October [5] Group 11: US Market Highlights - Boston Scientific (BSX.US) fell 17.59% after providing lower-than-expected guidance for fiscal year 2026. The company expects adjusted earnings per share to be between $3.43 and $3.49, slightly below analyst expectations [6] - Solar stocks surged, with Enphase Energy (ENPH.US) rising 38.6% following reports of interest from Elon Musk's teams in the Chinese solar supply chain [6]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The report highlights the strong performance of the medical beauty and cosmetics sectors, with significant growth potential driven by consumer demand for emotional value and safety in products [8][50] - Key companies in the medical beauty sector include Meili Tianyuan Medical Health, which is expanding through acquisitions and strong operational strategies, and in the cosmetics sector, brands like HBN and Banmu Huatian are leading with innovative product offerings and market strategies [8][24][34] Summary by Sections Market Review - The beauty and personal care index rose by 0.44% in January, ranking 24th among all sectors, underperforming the overall market [14][15] - Notable stock performances in January included SiHuan Pharmaceutical (+28.5%) and Yonghe Medical (+22.7%) in the medical beauty sector, while Yiwan Yichuang (+50.8%) and Ruoyu Chen (+8.1%) led in cosmetics [5][15] Medical Beauty - The approval of a new composite solution by Juzhi Biotechnology marks a significant advancement in the field, showcasing the company's R&D capabilities [6][19] - Meili Tianyuan announced a positive earnings forecast, projecting revenues of at least 3 billion yuan for 2025, reflecting a growth of over 16% year-on-year [22] Cosmetics - Banmu Huatian's parent company has filed for an IPO, aiming to leverage its strong market position in body care products [24] - HBN, a leading domestic skincare brand, has also submitted its IPO application, highlighting its innovative product lines and strong sales performance [34] Investment Recommendations - The report recommends focusing on high-quality companies in the medical beauty and cosmetics sectors that cater to emotional consumption trends, with specific mentions of Meili Tianyuan, Aimeike, and Ruoyu Chen among others [8][49] - In cosmetics, brands like Maogeping and Porlaia are highlighted for their strong market positions and innovative strategies [50][52]

Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD, with a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a combined implant solution [1] - CICC expresses optimism regarding the approval of this product, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - Looking ahead, CICC believes that the company's research and development strength, brand recognition, and team cohesion remain solid, suggesting that there are opportunities for investment as the cosmetics market recovers and contributions from aesthetic medicine increase [1]

Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD and a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first implant product aimed at improving cheek smoothness [1] - CICC expresses optimism regarding the product's approval, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - The long-term outlook from CICC suggests that the company's research and development strength, brand recognition, and team cohesion remain solid [1] - As the cosmetics market recovers and the contribution from aesthetic medicine increases, CICC recommends paying attention to investment opportunities in the company [1]

Core Viewpoint - The company has received regulatory approval for two key Class III medical devices, enhancing its position in the recombinant collagen market and addressing diverse aesthetic needs through innovative product offerings [1][2][3]. Group 1: Product Approvals - On January 15, 2026, the company received a Class III medical device registration certificate from the National Medical Products Administration of China for the "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" [1]. - The first approved product, "Recombinant Type I α1 Collagen Lyophilized Fiber," was the first recombinant collagen injection approved in China, designed for treating dynamic facial wrinkles [1]. Group 2: Product Innovation - The newly approved "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" is an injectable pre-mixed solution that combines equal concentrations of recombinant collagen (4.5 mg/mL) and sodium hyaluronate (4.5 mg/mL) [2]. - This product aims to improve skin smoothness through dermal injections, targeting the popular demand for skin quality improvement and hydration [2]. Group 3: Competitive Advantage - The company has established a strong competitive edge through a comprehensive "technology-brand-channel" strategy, supported by its proprietary recombinant collagen and synthetic biology technology platform [3]. - The approval of two Class III medical devices validates the platform's compliance and advanced nature, paving the way for future product expansion [3]. - The dual-brand strategy ("Kefumei" and "Keli Jin") and established hospital channels enhance the penetration of medical aesthetic products, transitioning the brand from skincare to medical-grade [3]. Group 4: Financial Projections - The company projects EPS of 1.82, 2.12, and 2.46 yuan for the years 2025 to 2027, with corresponding latest P/E ratios of 17.2, 14.8, and 12.8 times [3].

Investment Rating - The investment rating for the company is "Buy" (maintained) [4] Core Insights - The company has received approval for the world's first injectable recombinant collagen and hyaluronic acid composite solution, marking a significant milestone in its product offerings [8] - The company is expected to see a compound annual growth rate (CAGR) in revenue of 49.0% in 2023, followed by 57.2% in 2024, and a more moderate growth of 15.8% and 14.7% in 2026 and 2027 respectively [6][8] - The company has a strong pipeline in the aesthetic medicine sector, with two approved recombinant collagen products, which are anticipated to drive substantial revenue growth [8] Financial Summary - Closing price is HKD 35.40, with a market capitalization of HKD 37.91 billion [6][7] - Projected revenue for 2023 is RMB 3,524.14 million, increasing to RMB 7,428.23 million by 2027 [6] - Projected net profit for 2025-2027 is RMB 19.3 billion, RMB 22.6 billion, and RMB 25.4 billion respectively, with a notable decline of 6.3% in 2025 followed by growth in subsequent years [8] - The company maintains a low debt-to-asset ratio of 18.58% [7]

Investment Rating - The industry investment rating is "stronger than the market," indicating an expected performance that exceeds the market by more than 5% within the next six months [25]. Core Insights - The report highlights a divergence in the performance of various segments within the consumer sector, with a stable overall market performance but most sub-sectors underperforming compared to the broader market [4][6]. - There is an expectation for consumer demand to improve ahead of the Lunar New Year, driven by sufficient market liquidity [4]. - The tourism sector is showing potential for growth, with leading companies responding effectively to changing consumer demands [4]. - The beauty industry is experiencing steady growth, with a focus on companies that adapt quickly to market dynamics [4]. - The food and beverage sector is seeing a recovery in supply-demand relationships, particularly in dairy products, while the restaurant supply chain is stabilizing [4]. - In the liquor segment, leading companies are expected to maintain market share despite recent profit adjustments [4]. Market Performance Review - The Shanghai Composite Index fell by 0.57% during the week of January 12-16, with the media sector rising by 3.34% while other sectors like food and beverage and agriculture saw declines of 2.03% and 3.49% respectively [6][8]. Social Services - The report emphasizes the importance of companies that actively respond to changes in consumer demand, particularly in tourism and beauty sectors [4]. Industry Dynamics - The People's Bank of China has introduced measures to enhance structural monetary policy support, which may positively impact consumer spending and economic recovery [10]. - The Philippines has announced visa-free entry for Chinese citizens, which could boost tourism [11]. Company Announcements - Companies like Giant Biological and Proya are making strategic moves, such as product approvals and share buybacks, indicating proactive management in response to market conditions [13][19]. - The report notes significant developments in the liquor industry, including the launch of premium products and partnerships for promotional events [20].

Company Dynamics - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a recombinant collagen and hyaluronic acid composite solution [1] - The approval of this product is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Comments - The approval of the world's first recombinant collagen and hyaluronic acid composite solution for improving cheek smoothness represents the second medical aesthetic license obtained by the company [2] - The company plans to steadily advance the product's market launch and promotion through a diverse product portfolio, comprehensive channel network, and refined brand operations, aiming to strengthen its leading market position in the health and beauty sector [2] Future Prospects - The company has a rich pipeline of aesthetic medicine products, with the cross-linked neck wrinkle product having received national priority review qualification, and the cross-linked nasolabial fold product progressing smoothly [2] - The successful approval of the first two aesthetic products has validated the company's technological leadership and safety, with strong channel resources and operational experience expected to facilitate the rollout of future products [2] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for its cosmetics product matrix and channel expansion, with a rich reserve of new products, including multiple new offerings from the 可复美胶原修护, 焦点, and 秩序 series planned for launch [2] - The company is also upgrading its 可丽金 brand and plans to introduce new products by 2026, while collaborating with key influencers like Li Jiaqi to enhance marketing efforts [2] - The company aims to strengthen its online presence through influencer partnerships and expand its offline coverage in cinema lines, OTC, and CS/KA channels, as well as its own store layout [2] Profit Forecast and Valuation - The company maintains its net profit forecast for 2025-2026 and introduces a net profit estimate of 2.4 billion for 2027, with the current stock price corresponding to a 16x and 14x P/E for 2026-2027 [2] - The company maintains an outperform rating and a target price of 56 HKD, corresponding to a 25x and 23x P/E for 2026-2027, indicating a potential upside of 55% [2]

Core Viewpoint - CICC maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a 55% upside potential based on 25/23x P/E for 2026-2027 [1] Recent Events - On January 15, Giant Bio announced the approval of its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2] - The approval of this product is expected to expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [2] Future Product Pipeline - The company has a rich pipeline for aesthetic medicine, with cross-linked neck wrinkle products receiving priority review status and cross-linked nasolabial fold products progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience expected to enhance future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kemei" collagen repair series and plans for brand upgrades and new product launches in 2026 [4] - In terms of marketing, the company has strengthened its collaboration with key influencers, such as launching a New Year gift box with Li Jiaqi, and plans to enhance its online influencer matrix and self-operated team while expanding offline coverage [4]

Core Viewpoint - Company maintains a "outperforming the industry" rating for Giant Bio (02367) with a target price of HKD 56, indicating a potential upside of 55% based on 26-27 P/E ratios of 25x and 23x respectively, supported by strong R&D capabilities, brand recognition, and team cohesion [1] Recent Events - The company announced on January 15 that its "Recombinant Type I α1 Collagen and Sodium Hyaluronate Composite Solution" has been approved as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness [2][3] - The approval is expected to expand the company's aesthetic product matrix and validate its leading technological R&D capabilities [2] Future Product Pipeline - The company has a rich pipeline of aesthetic products, including cross-linked neck wrinkle products that have received priority review status and cross-linked nasolabial fold products that are progressing smoothly [3] - The approval of the first two aesthetic products has confirmed the company's technological leadership and safety, with strong channel resources and operational experience that can be reused for future product launches [3] Cosmetics Product Matrix and Channel Expansion - The company has a clear plan for product and channel expansion, with a rich reserve of new products including the "Kefumei Collagen Repair," "Focus," and "Order" series set to launch [4] - The company plans to upgrade the "Keli Jin" brand and introduce new products by 2026, while also enhancing collaboration with key influencers like Li Jiaqi for promotional activities [4] - There is a focus on strengthening online influencer networks and self-operated teams, as well as expanding offline channels including cinema lines, OTC, and CS/KA channel coverage [4]